Conversation with The Cancer Letter At ODAC without sponsors, FDA highlights safety signals in PI3K inhibitor trials April 15, 2022Vol.48 No.15By Paul Goldberg
Drugs & Targets FDA fast tracks targeted breast cancer immunotherapy Bria-IMT April 15, 2022Vol.48 No.15
In Brief FDA seeks $8.4B to further investments in public health programs, including $20M for Cancer Moonshot efforts April 01, 2022Vol.48 No.13
Guest Editorial Single-country clinical trial results: Are they applicable to other populations? March 25, 2022Vol.48 No.12By Edward S. Kim
Drugs & Targets FDA approves Opdualag for unresectable or metastatic melanoma March 25, 2022Vol.48 No.12
Drugs & Targets FDA approves Pluvicto for metastatic castration-resistant prostate cancer March 25, 2022Vol.48 No.12
Drugs & Targets FDA approves Opdivo and platinum-doublet chemotherapy for early-stage NSCLC March 11, 2022Vol.48 No.10
Drugs & Targets FDA grants priority review to Tibsovo in combination with azacitidine in previously untreated IDH1-mutated AML March 11, 2022Vol.48 No.10
Drugs & Targets FDA clinical trial guidances touch on Biden administration’s goals for advancing development of cancer treatments March 11, 2022Vol.48 No.10
